Evidence map›Paper›PMID 29339698›Full record

ArticleAnatolian journal of cardiology2018

Association of Interleukin-1 Gene cluster polymorphisms with coronary slow flow phenomenon.

Ferit Onur Mutluer, Dilek Ural, Barış Güngör, Osman Bolca, Tolga Aksu

Abstract read
In one paragraph

Article in Anatolian journal of cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Single Nucleotide Polymorphisms in Coronary Microvascular Dysfunction.Journal of the American Heart Association · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Interleukin-1 in Coronary Artery Disease.Current topics in medicinal chemistry · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Author`s Reply.Anatolian journal of cardiology · 2018
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ferit Onur Mutluer
Dilek Ural
Barış Güngör
Osman Bolca
Tolga AksuDepartment of Cardiology, Kocaeli Derince Trainig and Research Hospital, Kocaeli-Turkey. aksutolga@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCoronary slow flow phenomenon (CSFP) is characterized by the decreased rate of contrast progression in epicardial coronary arteries in the absence of significant coronary stenosis. Mounting evidence has showed a significant association between inflammation and CSFP severity. This study aimed to evaluate possible associations between interleukin-1 receptor antagonist (IL-1ra) gene variable number tandem repeat (VNTR), IL-1ß -511 single nucleotide (SNP), and IL-1ß+3954 SNP mutations with CSFP.

methodsForty-eight patients with CSFP and 62 controls with angiographically normal coronary arteries were prospectively enrolled in the study. Genotypes were assessed using the polymerase chain reaction (PCR)-based restriction fragment length polymorphism (PCR-RFLP) technique.

resultsHomozygote genotype for allele 2 of+3954 C>T 2/2 genotype was significantly more frequent in patients with CSFP than in the control group, whereas 1/2 genotype was more frequent in the control group (35.4% versus 14.5% for 2/2 genotype and 25% versus 35.5% for 1/2 genotype in CSFP and control groups, respectively, X

conclusionIL-1ß+3954 SNP mutations are significantly more common in patients with CSFP. It may suggest that the tendency for inflammation may contribute to the presence of this phenomenon.

Indexed as

Genetic Predisposition to DiseaseCase-Control StudiesCoronary AngiographyCoronary Artery DiseaseCross-Sectional StudiesFemaleHumansInterleukin 1 Receptor Antagonist ProteinMaleMiddle AgedMutationNo-Reflow PhenomenonPolymorphism, GeneticTurkeyWhite PeopleInterleukin 1 Receptor Antagonist Protein

Identifiers

PMID29339698
PMCPMC5864788

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.